Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21410465 | 0.93 | NPC1 (0.40) | L3MBTL1NPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL21416266 | 0.89 | NPC1 (0.40) | L3MBTL1NPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL25617801 | 0.86 | NPC1 (0.39) | L3MBTL1NPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL23245124 | 0.86 | NPC1 (0.37) | L3MBTL1NPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL21410614 | 0.86 | NPC1 (0.37) | L3MBTL1NPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL25619323 | 0.83 | NPC1 (0.43) | L3MBTL1NPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL25620690 | 0.83 | NPC1 (0.35) | NPC1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL25620167 | 0.81 | ALDH1A1 (0.50) | L3MBTL1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL25617660 | 0.80 | ALDH1A1 (0.46) | L3MBTL1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL25620124 | 0.80 | POLB (0.47) | L3MBTL1MAPTSMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661404-B2 | Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders | ACHILLES MEDICAL LIMITED (NZ) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661404-B2 | Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders | AKR1C2, AKR1C1, AKR1B1 | L3MBTL1 4126/4885NPC1 1212/4885MAPT 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.